Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Ryan Deschner is an analyst at Raymond James. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/18/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 03/12/2025 | INZY | Buy Now | Inozyme Pharma | $0.97 | 1132.54% | Ryan Deschner69% | $24 → $12 | Maintains | Outperform | Get Alert |
| 03/10/2025 | TRVI | Buy Now | Trevi Therapeutics | $6.55 | 342.75% | Ryan Deschner69% | $9 → $29 | Upgrade | Outperform → Strong Buy | Get Alert |
| 02/21/2025 | ARDX | Buy Now | Ardelyx | $5.32 | 144.36% | Ryan Deschner69% | $15 → $13 | Reiterates | Strong Buy → Strong Buy | Get Alert |
| 01/14/2025 | SPRY | Buy Now | ARS Pharmaceuticals | $11.53 | 142.84% | Ryan Deschner69% | $26 → $28 | Maintains | Strong Buy | Get Alert |
| 08/30/2024 | TRVI | Buy Now | Trevi Therapeutics | $6.55 | 37.4% | Ryan Deschner69% | → $9 | Initiates | → Outperform | Get Alert |
| 08/19/2024 | LQDA | Buy Now | Liquidia | $14.74 | 83.18% | Ryan Deschner69% | $27 → $27 | Upgrade | Outperform → Strong Buy | Get Alert |
| 08/16/2024 | LQDA | Buy Now | Liquidia | $14.74 | 83.18% | Ryan Deschner69% | → $27 | Initiates | → Outperform | Get Alert |
| 08/13/2024 | SPRY | Buy Now | ARS Pharmaceuticals | $11.53 | 90.81% | Ryan Deschner69% | $18 → $22 | Upgrade | Outperform → Strong Buy | Get Alert |
| 07/25/2024 | SPRY | Buy Now | ARS Pharmaceuticals | $11.53 | 56.11% | Ryan Deschner69% | → $18 | Initiates | → Outperform | Get Alert |
| 06/18/2024 | OMGA | Buy Now | Omega Therapeutics | — | — | Ryan Deschner69% | → $12 | Initiates | → Outperform | Get Alert |
